Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00321724
Other study ID # NCI-2012-01825
Secondary ID NCCTG-N048FU10CA
Status Completed
Phase Phase 2
First received May 2, 2006
Last updated January 14, 2013
Start date May 2006

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well AZD2171 works in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia. AZD2171 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer cells


Description:

OBJECTIVES:

I. Evaluate the response rate in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) treated with AZD2171.

II. Evaluate the toxicity of AZD2171 in patients with relapsed or refractory B-CLL.

III. Evaluate the complete response rate, progression-free and overall survival distributions, and duration of response in patients with relapsed or refractory B-CLL treated with AZD2171.

IV. Assess vascular endothelial growth factor receptor-2 (VEGFR-2) protein and phosphorylation levels in B-CLL cells using pretreatment samples and evaluate the association between Rai stage at study entry and clinical response to AZD2171.

V. Perform preclinical testing of AZD2171 in the induction of B-CLL cell apoptosis/cell death using pretreatment samples, and evaluate the ability to downregulate the phosphorylation status of VEGFR-2 of B-CLL cells by comparing in vitro samples with and without AZD2171.

VI. Study the differences in in vitro levels of B-CLL cell apoptosis/cell death and alteration of VEGFR-2 phosphorylation using pretreatment samples with and without AZD2171 and how these differences correlate with clinical outcomes.

VII. Assess if the clinical responses are associated with changes in bone marrow vascularity.

OUTLINE: This is a multicenter study.

Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sampling and biopsies at baseline and periodically throughout study for biomarker and correlative studies.

After completion of study therapy, patients are followed periodically for up to 5 years from study entry.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date
Est. primary completion date May 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histological confirmation of B-cell chronic lymphocytic leukemia (B-CLL)

- Peripheral blood lymphocyte count > 5,000/mm³

- Small to moderate peripheral blood lymphocytes with = 55% prolymphocytes

- Bone marrow aspirate with = 30% lymphoid cells

- Monoclonality of B lymphocytes by immunophenotyping, demonstrating all of the following:

- B-cell markers with CD5 antigen in the absence of other pan-T-cell markers (CD3, CD2, etc.)

- CD19 and/or CD20

- Expression of CD23 on the CLL cells OR dim B-cell expression of kappa or lambda light chains

- Disease must be refractory to or progressive after treatment with at least 1 course containing a purine nucleoside analog (e.g., fludarabine, cladribine, or pentostatin)

- Life expectancy > 6 months

- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

- Absolute neutrophil count = 1,500/mm³

- Platelet count = 50,000/mm³

- Hemoglobin = 8 g/dL

- Bilirubin = 1.5 times upper limit of normal (ULN)

- Patients with Gilbert's syndrome may have a bilirubin = 1.5 times ULN

- AST and ALT = 2.5 times ULN

- Creatinine = 1.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No history of allergies to compounds similar to AZD2171

- QTc prolongation < 500 msec

- No other significant ECG abnormality

- No history of familial long QT syndrome

- Proteinuria < 1+ by dipstick OR protein < 1 g/24 hr urine collection

- No known HIV positivity

- No New York Heart Association (NYHA) class III or IV disease

- NYHA class II disease controlled with treatment and monitoring allowed

- No other uncontrolled illness including, but not limited to, the following:

- Hypertension

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness or social situations that would limit compliance

- See Disease Characteristics

- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, anti-vascular endothelial growth factor (VEGF) treatment, or major surgery and recovered

- More than 30 days since prior investigational agents

- No concurrent drugs or biologics with proarrhythmic potential

- No other concurrent investigational agents

- No other concurrent anticancer therapy

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • B-cell Chronic Lymphocytic Leukemia
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Refractory Chronic Lymphocytic Leukemia

Intervention

Drug:
cediranib maleate
Given orally
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States North Central Cancer Treatment Group Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Confirmed response defined to be an objective status of complete remission [CR], nodular partial remission [nPR], and partial remission [PR] Ninety percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner. Up to 5 years No
Secondary Complete response rate estimated by the number of confirmed complete responses (CR) observed in the trial divided by the total number of evaluable patients Exact binomial 95% confidence intervals for the true complete response rate will be calculated. Up to 5 years No
Secondary Overall survival Estimated using the Kaplan-Meier method. From the date of registration to the date of death, assessed up to 5 years No
Secondary Time to progression as estimated by Kaplan-Meier method Estimated using the Kaplan-Meier method. From the date of registration to the date of disease progression, assessed up to 5 years No
Secondary Duration of response Estimated using the Kaplan-Meier method. From the date at which the patient's objective status is first noted to be a response to the date that progression or death is documented, assessed up to 5 years No
See also
  Status Clinical Trial Phase
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03045328 - Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Phase 2
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Active, not recruiting NCT01369849 - Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 1/Phase 2
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Terminated NCT00387426 - Sunitinib in Treating Patients With Idiopathic Myelofibrosis Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00006226 - Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Phase 2
Completed NCT00005803 - Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Phase 1/Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Active, not recruiting NCT04230304 - Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Phase 2
Recruiting NCT04007029 - Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04892277 - CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Active, not recruiting NCT04578600 - CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Phase 1
Completed NCT02240719 - Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer Phase 1
Terminated NCT01408043 - Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma N/A
Completed NCT01441882 - Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia Phase 2